Evidence map›Paper›PMID 32920953›Full record

ArticleMolecular oncology2020

Exploring the epigenetic regulation of telomerase reverse transcriptase (TERT) in human cancer cell lines.

Brittany A McKelvey, Martha A Zeiger, Christopher B Umbricht

Open access · goldAbstract readComment
In one paragraph

Article in Molecular oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Frontiers in oncology · 2024
    Article
  2. Review
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Brittany A McKelveyDepartment of Surgery, Johns Hopkins University, Baltimore, MD, USA.ORCID 0000-0001-9239-7153
Martha A ZeigerSurgical Oncology Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.ORCID 0000-0001-8998-0858
Christopher B UmbrichtDepartment of Surgery, Johns Hopkins University, Baltimore, MD, USA.ORCID 0000-0002-1993-0553
Johns Hopkins University · USNational Institutes of Health · US

Funding

Discovery and validation of early molecular breast cancer risk markers in benign breast diseaseR01CA222779 · NCI · JOHNS HOPKINS UNIVERSITY · PI UMBRICHT, CHRISTOPHER B · 2018 to 2023
$2.3M
NCI NIH HHS R01 CA222779
6 · The paper itself

Abstract

Telomerase regulation, including TERT promoter methylation, has been of long-standing interest to cancer biologists. Rowland et al. have now vastly expanded their ongoing characterization of TERT promoter methylation in cancer cells, analyzing the methylation patterns of 833 cell lines from 23 human cancers. They document a highly conserved pattern of hypomethylation around the proximal promoter, as well as a more heterogeneous region of hypermethylation further upstream, both associated with active TERT expression in cancer cells. They further describe the interplay between activating TERT promoter mutations and allelic methylation and transcription patterns. This valuable dataset represents the most extensive characterization of TERT promoter methylation in cancer cells to date and will help guide the future study of transcriptional regulation of telomerase. Comment on: https://doi.org/10.1002/1878-0261.12786.

Indexed as

NeoplasmsTelomeraseAllelesCell Line, TumorDNA MethylationEpigenesis, GeneticHumansMutationTelomeraseTERT protein, humanepigenetic regulationmonoallelic gene expressionmonoallelic methylationtelomerase reverse transcriptaseTERT promoter methylationTERT promoter mutation

Identifiers

PMID32920953
PMCPMC7530778
OpenAlexW3085917142

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.